Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Impact · against what's priced in

Aardvark Therapeutics' presentation of data from its terminated Phase III HERO trial confirms a failure in its lead clinical program. The discussion of efficacy and safety data from a halted trial provides little upside and reinforces the negative outlook for the company's pipeline.

AARD−0.60: No priced-in read yet

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

How each ticker is affected

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

How each ticker is affected

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Track these names every morning.

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Moderna leaked data was positive, what's hurting MRNA stock then?

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

How each ticker is affected

Next reads from the same story arc

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

How each ticker is affected

Next reads from the same story arc

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Track these names every morning.

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Moderna leaked data was positive, what's hurting MRNA stock then?